To fast-track therapies for people with Fanconi anemia (FA), it’s often best to start by examining progress that’s already been made in the general population. Large-scale studies such as The Cancer Genome Atlas (TCGA) have made it possible to detect...
Announcements
An update for FA families In the March 2019 issue of Trends in Genetics, researchers from St. Vincent’s Institute in Australia published a paper on the FA pathway and fertility. We asked the authors to provide a summary for FA families....
Announcements
The global Fanconi anemia gene therapy program is now open in the USA and Europe. In Europe, a new study, known as FANCOLEN-2, is available at CIEMAT/Hospital del Niño Jesús in Madrid, Spain. In the USA, a similar study is now...
Announcements
People with Fanconi anemia (FA) have a 500- to 700-fold increased risk of developing head and neck squamous cell carcinoma (HNSCC) tumors when compared to the general population. Conventional treatments available for non-FA-HNSCC such as radiation therapy and chemotherapy are...
Announcements
FARF t-shirts through the years Overview: To celebrate FARF’s 30th anniversary, we are asking our community to help design an original, limited edition FARF t-shirt. The winning design will earn you a scholarship to attend the FARF Symposium in downtown Chicago in September...
Announcements
One of FARF’s guiding principles is to gather the best researchers and clinicians in the FA community every year to share updates in research and care. In late 2018, we held the 30th Fanconi Anemia Scientific Symposium in Newport Beach,...
Announcements
